EICHORCondition: COVID-19 · Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Sobh | Anaheim, California, United States | — |
| Long Beach Clinical Trials, LLC | Long Beach, California, United States | — |
| Acclaim Clinical Research | San Diego, California, United States | — |
| Herco Research Center, Inc. | Coral Gables, Florida, United States | — |
| Midland Florida Clinical Research Center - Inf. Disease/Infectiology | DeLand, Florida, United States | — |
| Palm Springs Research Institute | Hialeah, Florida, United States | — |
| Sweet Hope Research Specialty, Inc | Hialeah, Florida, United States | — |
| Prestige Clinical Research Center Inc | Miami, Florida, United States | — |
| Cordova Research Institute, LLC | Miami, Florida, United States | — |
| Clinical Trials of Florida, LLC | Miami, Florida, United States | — |
| The Clinical Research Institute LLC | Miami Gardens, Florida, United States | — |
| Pembroke Clinical Trials | Pembroke Pines, Florida, United States | — |
+ 7 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05162365